Cardiometabolic Disorders News

Multicomponent exercise interventions were associated with greater improvements in measures of cardiometabolic health in people with overweight or obesity vs. single-component exercise interventions, according to a meta-analysis.

Adrenal gland volume is greater among adults with type 2 diabetes than without diabetes and might serve as a biomarker of metabolic status, according to study findings.

Intensive lifestyle intervention participants in the Look AHEAD randomized controlled trial who lost at least 10% of their body weight had a lower mortality risk compared with those in the control group, according to study data.

Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ejection fraction, AstraZeneca announced.

Adults with type 2 diabetes at high risk for cardiovascular disease add 1.7 life-years free of CVD when prescribed semaglutide along with standard diabetes care, according to study findings published in Diabetes Care.

Adults with type 2 diabetes who drink coffee had less decline in kidney function over time compared with non-coffee drinkers, according to study findings published in the Journal of Diabetes Investigation.

The U.S. Preventive Services Task Force has published a final recommendation that advises against the initiation of low-dose aspirin for primary CVD prevention in adults aged 60 years or older, a D-grade recommendation.

The SGLT2 inhibitor dapagliflozin safely reduced risk for worsening HF or CV death among adults with HF with reduced ejection fraction compared with placebo regardless of frailty status, researchers reported.

Polycystic ovary syndrome is a common endocrine disorder affecting reproductive-age women, yet the complexity and heterogeneity of PCOS have confounded researchers attempting to understand its long-term consequences.

The hyperandrogenic phenotype of polycystic ovary syndrome is the one most closely related to the things we think are “bad” for cardiovascular disease — obesity, insulin resistance — and those seem to be the driving factors of CVD risk. We also see examples of elevated CV risk in the setting of higher androgen levels in postmenopausal women and transgender men prescribed gender-affirming hormone therapy.